About Biogen (NASDAQ:BIIB)
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000
Debt
Debt-to-Equity Ratio0.42%
Current Ratio3.23%
Quick Ratio2.07%
Price-To-Earnings
Trailing P/E Ratio12.56
Forward P/E Ratio11.09
P/E Growth1.49
Sales & Book Value
Annual Sales$12.27 billion
Price / Sales4.72
Cash Flow$28.2913 per share
Price / Cash9.68
Book Value$66.35 per share
Price / Book4.13
Profitability
EPS (Most Recent Fiscal Year)$21.81
Net Income$2.54 billion
Net Margins23.54%
Return on Equity37.64%
Return on Assets20.32%
Miscellaneous
Employees7,300
Outstanding Shares211,560,000
Biogen (NASDAQ:BIIB) Frequently Asked Questions
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen (NASDAQ:BIIB) released its earnings results on Tuesday, April, 24th. The biotechnology company reported $6.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.93 by $0.12. The biotechnology company had revenue of $3.13 billion for the quarter, compared to the consensus estimate of $3.15 billion. Biogen had a net margin of 23.54% and a return on equity of 37.64%. The company's revenue was up 11.4% compared to the same quarter last year. During the same period in the prior year, the company posted $5.20 EPS. View Biogen's Earnings History.
When is Biogen's next earnings date?
What price target have analysts set for BIIB?
29 brokers have issued twelve-month price objectives for Biogen's shares. Their forecasts range from $17.00 to $433.00. On average, they expect Biogen's share price to reach $347.7833 in the next twelve months. View Analyst Ratings for Biogen.
What are Wall Street analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. Mizuho analysts commented, "We also note full year 2017 consensus is already above the company’s guidance on both top and bottom lines (guidance last updated in 2Q17) 1. Spinraza. We believe investors will continue to be focused on the performance of the Spinraza launch and information from management on uptake trends. At the recent JPM conference, BIIB commented that for Spinraza they see a benefit from the new launch period in large territories and then a moderate rate of growth, noting that they see reasonable growth in the US in the coming quarters and that a lot of the growth will come outside the US as new countries receive approvals. This was similar to commentary from management in the 3Q17 call. Consensus has 4Q over 3Q growth of 11% and 51% in the US and Ex-US for Spinraza." (1/18/2018)
- 2. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
- 3. Citigroup analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
- 4. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Novozymes (NVZMY), bluebird bio (BLUE), AveXis (AVXS), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Spark Therapeutics (ONCE), arGEN-X BV (ARGX), China Biologic Products (CBPO), Halozyme (HALO), CRISPR Therapeutics (CRSP) and Aerie Pharmaceuticals (AERI).
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Mr. Michel Vounatsos, CEO & Director (Age 56)
- Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 49)
- Mr. Jeffrey D. Capello, Exec. VP of Fin. & CFO (Age 53)
- Mr. Gregory F. Covino, VP of Fin. & Chief Accounting Officer (Age 52)
- Mr. Mark J. Hernon, Sr. VP & Chief Information Officer (Age 54)
Has Biogen been receiving favorable news coverage?
Media headlines about BIIB stock have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biogen earned a media sentiment score of 0.13 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.01 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Biogen's major shareholders?
Biogen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include
PRIMECAP MANAGEMENT COMPANY
(7.16%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.
How do I buy shares of Biogen?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of BIIB stock can currently be purchased for approximately $273.86.
How big of a company is Biogen?
Biogen has a market capitalization of $55.46 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $21.81 on an earnings per share basis. Biogen employs 7,300 workers across the globe.
How can I contact Biogen?
Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.
MarketBeat Community Rating for Biogen (BIIB)
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biogen (NASDAQ:BIIB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
29 Wall Street analysts have issued ratings and price targets for Biogen in the last 12 months. Their average twelve-month price target is $347.7833, suggesting that the stock has a possible upside of 26.99%. The high price target for BIIB is $433.00 and the low price target for BIIB is $17.00. There are currently 8 hold ratings and 21 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.72 | 2.72 | 2.72 | 2.64 |
| Ratings Breakdown: | 0 Sell Rating(s)
8 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
11 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $347.7833 | $370.9259 | $365.3571 | $341.0385 |
| Price Target Upside: | 26.99% upside | 32.52% upside | 1.12% downside | 10.86% upside |
Biogen (NASDAQ:BIIB) Consensus Price Target History
Biogen (NASDAQ:BIIB) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Biogen (NASDAQ:BIIB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biogen (NASDAQ BIIB) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 88.94%
Biogen (NASDAQ BIIB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/27/2018 | Alfred Sandrock | EVP | Sell | 259 | $290.83 | $75,324.97 | 6,553 |  |
| 2/20/2018 | Alfred Sandrock | EVP | Sell | 743 | $292.00 | $216,956.00 | 6,553 | |
| 2/15/2018 | Alfred Sandrock | EVP | Sell | 1,294 | $298.85 | $386,711.90 | 7,296 | |
| 1/9/2018 | Robert W Pangia | Director | Sell | 5,832 | $329.65 | $1,922,518.80 | 23,539 | |
| 12/29/2017 | Michel Vounatsos | CEO | Buy | 780 | $320.55 | $250,029.00 | | |
| 12/29/2017 | Michel Vounatsos | CEO | Buy | 780 | $320.55 | $250,029.00 | 4,879 | |
| 11/29/2017 | Alexander J Denner | Director | Buy | 30,000 | $317.36 | $9,520,800.00 | 10,029 | |
| 7/25/2017 | Susan H Alexander | EVP | Sell | 4,974 | $290.01 | $1,442,509.74 | 22,258 | |
| 7/19/2017 | Susan H Alexander | EVP | Sell | 7,758 | $285.00 | $2,211,030.00 | 27,232 | |
| 6/9/2017 | Brian S Posner | Director | Sell | 1,084 | $256.31 | $277,840.04 | 6,330 | |
| 5/1/2017 | Michel Vounatsos | CEO | Buy | 1,402 | $271.35 | $380,432.70 | | |
| 4/27/2017 | Alexander J. Denner | Director | Buy | 73,858 | $278.50 | $20,569,453.00 | | |
| 4/25/2017 | Paul J Clancy | VP | Sell | 9,892 | $290.00 | $2,868,680.00 | 10,813 | |
| 4/3/2017 | Alfred Sandrock | CMO | Sell | 1,981 | $274.08 | $542,952.48 | 7,060 | |
| 3/13/2017 | Paul J Clancy | VP | Sell | 9,891 | $291.55 | $2,883,721.05 | 20,705 | |
| 2/27/2017 | Michel Vounatsos | CEO | Buy | 1,333 | $285.39 | $380,424.87 | | |
| 1/9/2017 | Robert W Pangia | Director | Sell | 5,450 | $295.39 | $1,609,875.50 | 22,078 | |
| 10/4/2016 | Adriana Karaboutis | EVP | Sell | 262 | $311.94 | $81,728.28 | 7,579 | |
| 10/3/2016 | Adriana Karaboutis | EVP | Sell | 380 | $313.00 | $118,940.00 | 7,172 | |
| 9/22/2016 | Caroline Dorsa | Director | Sell | 27,570 | $314.00 | $8,656,980.00 | 19,663 | |
| 7/21/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | 54,779 | |
| 6/6/2016 | Adam Koppel | EVP | Sell | 555 | $290.00 | $160,950.00 | 2,402 | |
| 6/3/2016 | George A Scangos | CEO | Sell | 842 | $290.00 | $244,180.00 | 54,936 | |
| 6/1/2016 | George A Scangos | CEO | Sell | 3,855 | $289.74 | $1,116,947.70 | 56,265 | |
| 5/25/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | 59,633 | |
| 5/2/2016 | George A Scangos | CEO | Sell | 487 | $274.74 | $133,798.38 | 59,790 | |
| 4/6/2016 | Adam Koppel | EVP | Sell | 102 | $275.00 | $28,050.00 | 1,848 | |
| 4/6/2016 | George A Scangos | CEO | Sell | 157 | $280.00 | $43,960.00 | 60,277 | |
| 4/1/2016 | George A Scangos | CEO | Sell | 487 | $258.83 | $126,050.21 | 60,434 | |
| 3/1/2016 | George A Scangos | CEO | Sell | 487 | $261.37 | $127,287.19 | 60,921 | |
| 2/25/2016 | Adriana Karaboutis | EVP | Sell | 84 | $261.90 | $21,999.60 | 8,127 | |
| 2/25/2016 | Alfred Sandrock | CMO | Sell | 183 | $261.90 | $47,927.70 | 7,990 | |
| 2/17/2016 | Alfred Sandrock | Chief Medical Officer | Sell | 722 | $256.16 | $184,947.52 | 7,990 | |
| 2/17/2016 | George A Scangos | CEO | Sell | 487 | $256.16 | $124,749.92 | 59,848 | |
| 2/9/2016 | Alfred Sandrock | Chief Medical Officer | Sell | 852 | $246.54 | $210,052.08 | 7,740 | |
| 12/4/2015 | Alfred Sandrock | CMO | Sell | 441 | $277.00 | $122,157.00 | 7,740 | |
| 10/23/2015 | Alexander J Denner | Director | Buy | 310,000 | $277.47 | $86,015,700.00 | 7,890 | |
| 7/27/2015 | Stelios Papadopoulos | Director | Buy | 10,000 | $304.88 | $3,048,800.00 | | |
| 6/19/2015 | Douglas E Williams | EVP | Sell | 3,841 | $410.00 | $1,574,810.00 | | |
| 6/1/2015 | George A Scangos | CEO | Sell | 1,362 | $398.87 | $543,260.94 | | |
| 4/1/2015 | George A Scangos | CEO | Sell | 1,362 | $423.20 | $576,398.40 | | |
| 3/25/2015 | John Cox | EVP | Sell | 12,010 | $449.06 | $5,393,210.60 | | |
| 3/20/2015 | Eric K Rowinsky | Director | Sell | 11,667 | $475.00 | $5,541,825.00 | | |
| 3/19/2015 | Eric K Rowinsky | Director | Sell | 2,333 | $436.14 | $1,017,514.62 | | |
| 3/17/2015 | Eric K Rowinsky | Director | Sell | 4,667 | $425.45 | $1,985,575.15 | | |
| 3/10/2015 | Robert W Pangia | Director | Sell | 3,625 | $413.40 | $1,498,575.00 | | |
| 3/2/2015 | Alfred Sandrock | SVP | Sell | 3,174 | $409.49 | $1,299,721.26 | | |
| 2/17/2015 | Steven H Holtzman | EVP | Sell | 2,128 | $389.11 | $828,026.08 | | |
| 2/10/2015 | Alfred Sandrock | SVP | Sell | 1,143 | $398.11 | $455,039.73 | | |
| 2/2/2015 | Kenneth Dipietro | EVP | Sell | 1,656 | $389.03 | $644,233.68 | | |
| 12/15/2014 | Spyridon Artavanis-Tsakonas | SVP | Sell | 1,981 | $346.50 | $686,416.50 | | |
| 12/2/2014 | Steven H Holtzman | EVP | Sell | 1,749 | $335.65 | $587,051.85 | | |
| 11/11/2014 | Steven H Holtzman | EVP | Sell | 1,750 | $330.00 | $577,500.00 | | |
| 11/3/2014 | George A Scangos | CEO | Sell | 1,128 | $320.78 | $361,839.84 | | |
| 10/1/2014 | George A Scangos | CEO | Sell | 1,127 | $330.97 | $373,003.19 | | |
| 10/1/2014 | Steven H Holtzman | EVP | Sell | 1,750 | $330.97 | $579,197.50 | | |
| 8/1/2014 | George A Scangos | CEO | Sell | 1,128 | $332.93 | $375,545.04 | | |
| 7/16/2014 | George A Scangos | CEO | Sell | 12,316 | $312.37 | $3,847,148.92 | | |
| 5/19/2014 | Steven Holtzman | EVP | Sell | 1,221 | $289.15 | $353,052.15 | 5,749 | |
| 5/1/2014 | George Scangos | CEO | Sell | 2,123 | $285.56 | $606,243.88 | 24,019 | |
| 4/17/2014 | Steven Holtzman | EVP | Sell | 1,221 | $291.00 | $355,311.00 | 6,970 | |
| 4/1/2014 | George Scangos | CEO | Sell | 2,123 | $308.42 | $654,775.66 | 26,142 | |
| 4/1/2014 | Robert Pangia | Director | Sell | 6,250 | $308.42 | $1,927,625.00 | 14,003 | |
| 3/31/2014 | Brian Posner | Director | Sell | 3,000 | $296.76 | $890,280.00 | 6,435 | |
| 3/20/2014 | Caroline Dorsa | Director | Sell | 10,000 | $348.88 | $3,488,800.00 | 14,468 | |
| 3/19/2014 | Douglas Williams | EVP | Sell | 3,505 | $352.29 | $1,234,776.45 | 7,976 | |
| 3/17/2014 | Steven Holtzman | EVP | Sell | 1,221 | $334.83 | $408,827.43 | 8,191 | |
| 3/11/2014 | Stuart Kingsley | EVP | Sell | 8,428 | $336.83 | $2,838,803.24 | 3,511 | |
| 3/3/2014 | George Scangos | CEO | Sell | 2,942 | $335.79 | $987,894.18 | 54,389 | |
| 2/26/2014 | Alfred Sandrock | SVP | Sell | 1,048 | $342.17 | $358,594.16 | 21,407 | |
| 2/18/2014 | Steven Holtzman | EVP | Sell | 1,222 | $327.90 | $400,693.80 | 9,412 | |
| 2/13/2014 | Kenneth Dipietro | EVP | Sell | 1,290 | $316.81 | $408,684.90 | | |
| 2/11/2014 | Alfred Sandrock | SVP | Sell | 2,085 | $314.31 | $655,336.35 | 13,667 | |
| 2/11/2014 | George Scangos | CEO | Sell | 2,456 | $314.31 | $771,945.36 | 52,961 | |
| 2/4/2014 | Kenneth Dipietro | EVP | Sell | 1,655 | $299.01 | $494,861.55 | | |
| 1/21/2014 | Eric Rowinsky | Director | Sell | 2,020 | $310.09 | $626,381.80 | 10,440 | |
| 1/15/2014 | Lynn Schenk | Director | Sell | 1,000 | $297.48 | $297,480.00 | 3,325 | |
| 1/8/2014 | William Young | Director | Sell | 15,000 | $285.11 | $4,276,650.00 | 18,509 | |
| 1/6/2014 | Robert Pangia | Director | Sell | 6,250 | $278.03 | $1,737,687.50 | 14,003 | |
| 12/2/2013 | Lynn Schenk | Director | Sell | 1,000 | $291.71 | $291,710.00 | 3,325 | |
| 11/22/2013 | Raymond Pawlicki | SVP | Sell | 4,000 | $288.00 | $1,152,000.00 | 8,710 | |
| 11/1/2013 | George A Scangos | CEO | Sell | 2,239 | $245.57 | $549,831.23 | | |
| 11/1/2013 | Lynn Schenk | Director | Sell | 1,000 | $245.00 | $245,000.00 | | |
| 10/22/2013 | Alfred Sandrock | SVP | Sell | 15,030 | $250.11 | $3,759,153.30 | | |
| 9/18/2013 | Paul Clancy | CFO | Sell | 26,785 | $245.00 | $6,562,325.00 | 7,087 | |
| 9/17/2013 | Steven Holtzman | EVP | Sell | 3,501 | $238.98 | $836,668.98 | 4,885 | |
| 9/16/2013 | Paul Clancy | CFO | Sell | 99,030 | $238.27 | $23,595,878.10 | 7,087 | |
| 9/16/2013 | Raymond Pawlicki | SVP | Sell | 4,000 | $238.03 | $952,120.00 | 8,710 | |
| 9/3/2013 | George Scangos | CEO | Sell | 2,239 | $214.40 | $480,041.60 | 43,522 | |
| 8/26/2013 | Douglas Williams | EVP | Sell | 4,368 | $211.35 | $923,176.80 | 4,571 | |
| 8/1/2013 | George A Scangos | CEO | Sell | 2,239 | $218.82 | $489,937.98 | | |
| 7/16/2013 | George A Scangos | CEO | Sell | 2,239 | $223.94 | $501,401.66 | | |
| 6/14/2013 | Alexander J Denner | Director | Sell | 2,900 | $212.00 | $614,800.00 | | |
| 6/11/2013 | Brian S Posner | Director | Sell | 2,020 | $219.62 | $443,632.40 | | |
| 6/10/2013 | Lynn Schenk | Director | Sell | 2,000 | $225.82 | $451,640.00 | | |
| 6/3/2013 | George A Scangos | CEO | Sell | 1,598 | $234.16 | $374,187.68 | | |
| 6/3/2013 | Stephen A Sherwin | Director | Sell | 12,825 | $233.26 | $2,991,559.50 | | |
| 5/28/2013 | Robert W Pangia | Director | Sell | 5,900 | $237.23 | $1,399,657.00 | | |
| 12/27/2012 | Alexander J Denner | Director | Sell | 7,980 | $148.62 | $1,185,987.60 | | |
(Data available from 1/1/2013 forward)
Biogen (NASDAQ BIIB) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Brian Skorney on Biogen Earnings
www.bloomberg.com - April 26 at 5:19 PM |
 | Analyst Recommendations for Biogen in April
finance.yahoo.com - April 26 at 5:19 PM |
 | FY2020 EPS Estimates for Biogen (BIIB) Lowered by Analyst
www.americanbankingnews.com - April 26 at 11:28 AM |
| FY2020 EPS Estimates for Biogen Boosted by William Blair (BIIB)
www.americanbankingnews.com - April 26 at 11:28 AM |
| Biogen's (BIIB) Neutral Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - April 26 at 10:32 AM |
| Jefferies Group Weighs in on Biogen's Q3 2018 Earnings (BIIB)
www.americanbankingnews.com - April 26 at 9:50 AM |
| Piper Jaffray Analysts Reduce Earnings Estimates for Biogen (BIIB)
www.americanbankingnews.com - April 26 at 9:24 AM |
 | 3 Things In Biotech, April 25: Biogen Advances, Prothena Crashes, Lilly Survives
seekingalpha.com - April 26 at 8:14 AM |
| Blog Exposure - Galapagos Commenced First Clinical Trial FALCON with Investigational Triple Combination Therapy in Cystic Fibrosis Patients
finance.yahoo.com - April 26 at 8:14 AM |
| Biogen’s Fampyra and Interferons in 1Q18
finance.yahoo.com - April 26 at 8:14 AM |
 | Biotech Bounceback: Amgen, Biogen Gain Believers
www.barrons.com - April 25 at 5:30 PM |
| Biogen Q1 2018: Too Cheap To Ignore
seekingalpha.com - April 25 at 5:30 PM |
| Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales
finance.yahoo.com - April 25 at 5:30 PM |
 | Biogen Posts Double-Digit Profits, Has Cash to Burn
www.fool.com - April 25 at 4:10 PM |
| $6.24 EPS Expected for Biogen (BIIB) This Quarter
www.americanbankingnews.com - April 25 at 3:14 PM |
| Biogen (BIIB) Price Target Raised to $369.00 at Morgan Stanley
www.americanbankingnews.com - April 25 at 11:36 AM |
| Biogen (BIIB) Receives "Outperform" Rating from Citigroup
www.americanbankingnews.com - April 25 at 10:49 AM |
| Biogen (BIIB) PT Set at $385.00 by Guggenheim
www.americanbankingnews.com - April 25 at 10:30 AM |
| Stifel Nicolaus Analysts Give Biogen (BIIB) a $425.00 Price Target
www.americanbankingnews.com - April 25 at 10:30 AM |
| Biogen (BIIB) Given a $375.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - April 25 at 10:30 AM |
| Goldman Sachs Lowers Biogen (BIIB) to Buy
www.americanbankingnews.com - April 25 at 10:20 AM |
| Biogen (BIIB) Raised to Outperform at Robert W. Baird
www.americanbankingnews.com - April 25 at 10:14 AM |
| Credit Suisse Group Reiterates "$384.00" Price Target for Biogen (BIIB)
www.americanbankingnews.com - April 25 at 9:58 AM |
| Biogen (BIIB) PT Set at $325.00 by Leerink Swann
www.americanbankingnews.com - April 25 at 9:58 AM |
| Q2 2019 EPS Estimates for Biogen (BIIB) Reduced by Analyst
www.americanbankingnews.com - April 25 at 9:50 AM |
 | Biogen (BIIB) PT Lowered to $385 at Guggenheim
www.streetinsider.com - April 25 at 8:17 AM |
| Biogen Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - April 25 at 8:17 AM |
| Spinraza’s flat sales rattle investors but Biogen sees momentum for key rare-disease therapy
finance.yahoo.com - April 25 at 8:17 AM |
 | Biogen Investors Are Losing Patience
www.wsj.com - April 24 at 8:27 PM |
| SunTrust Banks Analysts Give Biogen (BIIB) a $321.00 Price Target
www.americanbankingnews.com - April 24 at 7:30 PM |
| BIOGEN INC.
www.streetinsider.com - April 24 at 5:37 PM |
 | Biogen Inc. Q1 adjusted earnings Beat Estimates
www.nasdaq.com - April 24 at 5:37 PM |
 | Biogen revenue climbs, while Spinraza, Tecfidera sales miss
www.cnbc.com - April 24 at 5:37 PM |
| Biogen's Strange MS Quandary Requires Stronger Medicine
www.bloomberg.com - April 24 at 5:37 PM |
| Biogen Rallies After Spinraza, Multiple Sclerosis Revenue Come In Light
finance.yahoo.com - April 24 at 5:37 PM |
| Biogen (BIIB) PT Lowered to $0.00 at Piper Jaffray
www.americanbankingnews.com - April 24 at 4:54 PM |
| Biogen (BIIB) Receives "Buy" Rating from Cowen
www.americanbankingnews.com - April 24 at 4:18 PM |
| Mizuho Analysts Give Biogen (BIIB) a $433.00 Price Target
www.americanbankingnews.com - April 24 at 4:18 PM |
| Biogen (BIIB) Receives "Hold" Rating from Jefferies Group
www.americanbankingnews.com - April 24 at 4:18 PM |
| Biogen (BIIB) Posts Earnings Results, Beats Expectations By $0.12 EPS
www.americanbankingnews.com - April 24 at 9:17 AM |
| Your Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update
seekingalpha.com - April 24 at 8:17 AM |
| Biogen Q1 18 Earnings Conference Call At 8:30 AM ET
www.nasdaq.com - April 24 at 8:17 AM |
 | BRIEF-Biogen Reports Quarterly Revenues Of $3.1 Billion
www.reuters.com - April 24 at 8:17 AM |
 | Biogen reports Q1 profit beat, sales miss
www.marketwatch.com - April 24 at 8:17 AM |
| Biogen quarterly profit jumps on higher Spinraza sales
finance.yahoo.com - April 24 at 8:17 AM |
| Biogen revenue climbs; Spinraza, Tecfidera sales miss
finance.yahoo.com - April 24 at 8:17 AM |
| Biogen stock drops 2% after Q1 sales miss
finance.yahoo.com - April 24 at 8:17 AM |
| Biogen's SMA med Spinraza shows longer-term treatment effect in extension study
seekingalpha.com - April 23 at 5:15 PM |
| Nomura/Instinet Reiterates Buy on Biogen (BIIB) Following Announced IONS Collaboration
www.streetinsider.com - April 23 at 5:15 PM |
| Your Daily Pharma Scoop: Abeona's ABO-202, Revance Update, Ionis/Biogen's New Collaboration
seekingalpha.com - April 23 at 8:13 AM |
Biogen (NASDAQ:BIIB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Biogen (NASDAQ:BIIB) Income Statement, Balance Sheet and Cash Flow Statement
Biogen (NASDAQ BIIB) Stock Chart for Thursday, April, 26, 2018
Loading chart…
